News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
707,232 Results
Type
Article (41905)
Company Profile (332)
Press Release (664995)
Section
Business (210162)
Career Advice (2080)
Deals (36581)
Drug Delivery (100)
Drug Development (82845)
Employer Resources (171)
FDA (16488)
Job Trends (15358)
News (355478)
Policy (33832)
Tag
Academia (2574)
Alliances (51176)
Alzheimer's disease (1274)
Approvals (16430)
Artificial intelligence (157)
Bankruptcy (362)
Best Places to Work (11710)
Biotechnology (215)
Breast cancer (191)
Cancer (1377)
Cardiovascular disease (115)
Career advice (1741)
Cell therapy (278)
Clinical research (66192)
Collaboration (480)
Compensation (258)
COVID-19 (2612)
C-suite (110)
Data (1382)
Diabetes (169)
Diagnostics (6253)
Earnings (86572)
Employer resources (149)
Events (112837)
Executive appointments (390)
FDA (17146)
Funding (426)
Gene therapy (206)
GLP-1 (628)
Government (4452)
Healthcare (18871)
Infectious disease (2703)
Inflammatory bowel disease (115)
Interviews (320)
IPO (16607)
Job creations (4052)
Job search strategy (1488)
Layoffs (437)
Legal (8326)
Lung cancer (199)
Manufacturing (208)
Medical device (13296)
Medtech (13301)
Mergers & acquisitions (20110)
Metabolic disorders (460)
Neuroscience (1600)
NextGen Class of 2024 (6625)
Non-profit (4515)
Northern California (1681)
Obesity (264)
Opinion (207)
Patents (119)
People (58395)
Pharmaceutical (98)
Phase I (20498)
Phase II (29123)
Phase III (21845)
Pipeline (513)
Postmarket research (2651)
Preclinical (8730)
Radiopharmaceuticals (241)
Rare diseases (267)
Real estate (6240)
Regulatory (22489)
Research institute (2359)
Resumes & cover letters (358)
Southern California (1454)
Startups (3712)
United States (15175)
Vaccines (581)
Weight loss (194)
Date
Today (138)
Last 7 days (565)
Last 30 days (2575)
Last 365 days (35833)
2024 (35329)
2023 (40630)
2022 (51797)
2021 (56329)
2020 (54794)
2019 (47402)
2018 (35771)
2017 (33137)
2016 (32663)
2015 (38615)
2014 (32516)
2013 (27630)
2012 (29729)
2011 (30487)
2010 (28497)
Location
Africa (776)
Arizona (201)
Asia (40120)
Australia (6418)
California (3788)
Canada (1438)
China (304)
Colorado (173)
Connecticut (178)
Europe (85439)
Florida (531)
Georgia (133)
Illinois (389)
Indiana (231)
Maryland (627)
Massachusetts (2980)
Michigan (172)
Minnesota (288)
New Jersey (1101)
New York (1071)
North Carolina (754)
Northern California (1681)
Ohio (145)
Pennsylvania (920)
South America (1157)
Southern California (1454)
Texas (551)
Utah (106)
Washington State (403)
707,232 Results for "rigel pharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
Rigel Pharmaceuticals Completes Transfer of GAVRETO® (pralsetinib) New Drug Application
Rigel Pharmaceuticals, Inc. (“Rigel”) (Nasdaq: RIGL) today announced the completion of the transfer to Rigel of the New Drug Application (NDA) for GAVRETO®.
June 24, 2024
·
10 min read
Business
Optime Care Announces Enhanced Partnership with Rigel Pharmaceuticals for GAVRETO® Patients
Optime Care, a nationally recognized specialty pharmacy and an AscellaHealth Company, today announces a contractual partnership with Rigel Pharmaceuticals, Inc., effective July 1, 2024, bringing its comprehensive suite of services to support patients using GAVRETO® (pralsetinib).
June 27, 2024
·
8 min read
Press Releases
Optime Care Expands Partnership with Rigel Pharmaceuticals to Include Commercial Distribution for TAVALISSE®
October 17, 2024
·
6 min read
Biotech Bay
Rigel Announces Reverse Stock Split - June 25, 2024
Rigel Pharmaceuticals, Inc. announced that it will effect a reverse stock split of its issued and outstanding shares of common stock at a ratio of 1-for-10, effective at 12:01 a.m. Eastern Time on Thursday, June 27, 2024.
June 25, 2024
·
5 min read
Biotech Bay
Rigel Announces Five Presentations at the EHA2024 Hybrid Congress
Rigel Pharmaceuticals, Inc. announced one oral and four poster presentations at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain being held June 13-16, 2024, and online.
June 14, 2024
·
16 min read
Biotech Bay
Rigel to Present at the Jefferies Global Healthcare Conference
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Raul Rodriguez , the company’s president and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:30 am ET in New York, NY.
May 30, 2024
·
1 min read
Deals
Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®
Rigel Pharmaceuticals, Inc. (“Rigel”) (Nasdaq: RIGL) today announced that it has entered into a definitive agreement to acquire the U.S. rights to GAVRETO® (pralsetinib) from Blueprint Medicines Corporation (“Blueprint”).
February 22, 2024
·
12 min read
Biotech Bay
Rigel Highlights New Data in Three Poster Presentations at the 2024 ASCO Annual Meeting
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the presentation of three posters at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL today and online.
June 3, 2024
·
13 min read
Press Releases
Rigel to Present at the Jefferies London Healthcare Conference 2024
November 13, 2024
·
1 min read
Business
Rigel Reports First Quarter 2024 Financial Results and Provides Business Update
Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2024.
May 7, 2024
·
25 min read
1 of 70,724
Next
